Irinotecan is a camptothecin analogue with high antitumor efficacy by inhibiting topoisomerase I. This drug was approved for the treatment of a wide variety of solid tumors such as colorectal cancer, and has been widely used in Japan. Especially, combination therapy of irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) has been proven to be highly effective for the treatment of metastatic colorectal cancer.
The FOLFIRI has become a key regimen in the treatment of metastatic colorectal cancer as a standard option of chemotherapy in many countries including the United States, European countries and also Japan.
Irinotecan is a prodrug that is metabolized by carboxylesterase 2 to generate its active metabolite SN-38, which exerts antitumor effects and causes adverse drug reactions ( Fig. 1) . SN-38 thus formed is further glucuronidated by a hepatic UDP-glucuronosyltransferase 1A1 (UGT1A1), to yield a polar inactive SN-38 glucuronide (SN-38G). 3) There are various genetic variants in the UGT1A1 gene that influence the expression or function of encoded protein. UGT1A1*28 is an allele with (TA) 7 TAA within the promoter of the UGT1A1 gene that has been known to be associated with reduced glucuronidation capacity of SN-38 as well as with irinotecan-related dose-limiting toxicities, including severe myelosuppression and delayed-type diarrhea. [4] [5] [6] UGT1A1*6 is an allele including a single nucleotide polymorphism (211GϾA) causing an amino acid change (G71R) that relates to reduced catalytic activity. This polymorphism allele is seen in Asian populations including Japanese with a high frequency (0.15 to 0.25), but not in whites. [7] [8] [9] The UGT1A1*6 has been increasingly clarified to be associated with reduced SN-38 glucuronidation and irinotecan-induced severe toxicity in Asian populations. [8] [9] [10] Irinotecan, SN-38 and SN-38G are known to be excreted into bile by members of the ATP-binding cassette transporters. ATP-binding cassette, sub-family C, number 2 (ABCC2) is a transporter which is expressed at the apical membrane of the liver and is responsible for the biliary excretion of irinotecan and its metabolites. 11, 12) It has been reported that there are a variety of polymorphisms alleles in the ABCC2 gene. [13] [14] [15] The polymorphisms in the ABCC2 gene causing reduced transcriptional activity or decreased transport activity might reduce the biliary excretion of irinotecan and its metabolites. Accordingly, the variants in ABCC2 as well as in UGT1A1 genes might affect the pharmacokinetics (PK) of irinotecan. However, there have been few reports on the relationship between the PK of irinotecan and genetic variants in the ABCC2 gene.
Therefore, we examined the effects of polymorphisms in the ABCC2 gene on the PK of irinotecan and its metabolites in Japanese patients with metastatic colorectal cancer treated with FOLFIRI.
MATERIALS AND METHODS
Materials Irinotecan, SN-38 and SN-38G were kindly supplied by Yakult Honsha (Tokyo, Japan). All chemicals and solvents were of the highest grade commercially available.
Patients The study group for ABCC2 genotyping was comprised with 67 Japanese patients (male/female, 42/25) with various solid tumors (40 colorectal, 14 stomach, 5 ovarian, 4 lung and 4 others) who received irinotecan monotherapy or various regimens of irinotecan-based combined chemotherapy. The median age of the patients was 61 years (42 to 85). The protocol of irinotecan PK and pharmacogenetic study was approved by the Institutional Review Board of Saitama Medical University. All patients were asked for a written informed consent for their peripheral blood samples and medical information to be used for research purpose. These patients included those with metastatic colorectal cancer receiving FOLFIRI. The relation between the ABCC2 genotypes or diplotypes and irinotecan PK was analyzed with the subset of patients receiving FOLFIRI.
Treatments For the FOLFIRI regimen, irinotecan was administered at 2-week intervals at doses of 150 or 180 mg/m 2 . Irinotecan was infused over the course of 90 min. ABCC2 Genotyping Genomic DNA was extracted from 200 ml of peripheral blood, which had been stored at Ϫ80°C until analysis, with the use of a QIAamp Blood Kit (QIA-GEN GmbH, Hilden, Germany).
Six polymor phisms (Ϫ1549GϾA, Ϫ1023GϾA, Ϫ1019AϾG, Ϫ24CϾT, 1249GϾA [V417I] and 3972CϾT [I324I], based on assigning the A in the translation start codon as ϩ1) were examined by direct DNA sequencing. ABCC2 gene fragments containing these polymorphic sites were amplified by means of polymerase chain reaction (PCR) according to the methods of Ito et al., 15) with some modifications. Briefly, forward and reverse primers used to amplify an ABCC2 gene fragment from Ϫ1632 to Ϫ1419 were ABCC2-1549F2 (5Ј-AAA AGT GTC TGT TCA AGT CC-3Ј) and ABCC2-1549R2 (5Ј-GTG AAT TGT ATG GAC CTT GT-3Ј) and those from Ϫ1157 to Ϫ908 were ABCC2-1019F (5Ј-GGA TAC CGC ATG GGT GGT TC-3Ј) and ABCC2-1019R (5Ј-ACT ACA GGC ACA TGC CCA CA-3Ј), respectively. Annealing temperature was 54°C, except for the amplification of exon 10 containing the position of 1249 (52°C) and exon 28 including the position of 3972 (56°C). PCR products were directly sequenced on a 3130 genetic analyzer (Applied Biosystems, CA, U.S.A.).
Determination of Irinotecan, SN-38 and SN-38G
Blood samples for PK analysis were obtained during the first cycle of irinotecan treatment. Blood samples were taken from the opposite site of the arm of the infusion site right before the beginning of irinotecan infusion and 0, 0.25, 0.5, 1, 2, 4, 8, and 24 h after the end of the infusion. The samples were immediately centrifuged, and resulting plasma samples were stored at Ϫ80°C until analysis.
Total (lactone and carboxylate) plasma concentrations of irinotecan, SN-38, and SN-38G were analyzed by a reversephase high-performance liquid chromatography as described by Araki et al. 10) and Fujita et al. 16) The lower limit of quantification for irinotecan was 5 ng/ml (7.4 nM), and those for SN-38 and SN-38G were 0.5 ng/ml (1.2 and 0.88 nM, respectively). The intraassay coefficients of variation for irinotecan, SN-38 and SN-38G were 3.2, 4.7 and 6.1%, respectively. The interassay coefficients of variation for irinotecan, SN-38 and SN-38G were 8.8, 6.7 and 7.4%, respectively.
PK Parameters
The areas under the time-concentration curve AUC (mM · h) of irinotecan, SN-38 and SN-38G from the beginning of the infusion to the time of the last blood sampling were calculated by the linear trapezoidal rule with a computer program (WinNonlin version 5.1 software, Pharsight Corporation, Mountain View, CA, U.S.A.) and normalized by irinotecan dose.
Statistical Analysis Allele and genotype frequencies for each polymorphic allele in the ABCC2 gene were determined by using SNPAlyze 5.1 (Dynacom, Yokohama, Japan). The significance of deviations from Hardy-Weinberg equilibrium was also tested with the program SNPAlyze 5.1. Linkage disequilibrium analysis to make a pairwise 2-dimensional map of correlation coefficients r 2 and DЈ among single nucleotide polymorphisms in the ABCC2 gene was performed with SNPAlyze 5.1. Haplotype and diplotype analyses were also performed by an expectation-maximization-based algorithm using SNPAlyze 5.1. The Mann-Whitney U test was used to compare the AUC of irinotecan, SN-38 and SN-38G according to ABCC2 genotypes or diplotypes, and the chi-square test was employed to analyze the association of ABCC2 diplotypes or genotypes with irinotecan toxicity (JMP version 6 software, SAS Institute, Inc., Cary, NC, U.S.A.). A pvalue of less than 0.05 was taken to indicate a statistically significant difference.
RESULTS

ABCC2 Genotypes and Haplotypes
The genotypes of the ABCC2 were determined in the 67 Japanese patients with cancer. The results are shown in Table 1 . The allele frequencies of the Ϫ1549GϾA, Ϫ1023GϾA, Ϫ1019AϾG, Ϫ24CϾT, 1249GϾA and 3972CϾT were 0.157, 0.366, 0.157, 0.142, 0.134 and 0.172, respectively. The allele frequencies of the Ϫ24CϾT, 1249GϾA and 3972CϾT are almost comparable to those previously obtained with healthy Japanese. 15) All polymorphisms were in Hardy-Weinberg equilibrium. The results of the linkage disequilibrium analyses are shown in Table 2 . We found that Ϫ1549GϾA was highly linked with Ϫ1019AϾG, Ϫ24CϾT and 3972CϾT (r Ϫ1023GϾA and Ϫ1249GϾA were not linked with any polymorphisms examined.
Five major haplotypes estimated are shown in Table 3 .
Characteristics of Patients Treated with FOLFIRI A total of 31 Japanese patients with metastatic colorectal cancer who received FOLFIRI were enrolled in the present study. The patient characteristics and clinical outcomes after treatment with FOLFIRI are summarized in Table 4 . All of the patients showed performance status 0 or 1. Hepatic and renal functions were normal. Twenty-one patients showed partial response or stable disease by FOLFIRI treatment. Hematologic and non-hematologic toxicity (grade 3Յ) occurred in 12 and 5 patients, respectively.
Association of ABCC2 Diplotypes or Genotypes with Irinotecan PK Association between the respective AUC of irinotecan, SN-38 and SN-38G normalized by irinotecan dose and ABCC2 diplotypes or genotypes was examined. The patients with diplotypes harboring at least one haplotype IV that consisted of 1249GϾA showed the significantly lower AUC of irinotecan than others (pϭ0.011) ( Table 5 ). The AUC of SN-38 and SN-38G was also lower in patients with diplotypes carrying at least one haplotype IV, although the results were not significant. Patients heterozygous or homozygous for the haplotype I that contained Ϫ1023GϾA polymorphism demonstrated the significantly lower AUC of SN-38 than others (pϭ0.023) ( Table 5) .
Patients possessing A/A or G/A genotypes at 1249 resulted in the significantly lower AUC of irinotecan (pϭ0.011) ( Table 5 ). Patients having A/A or G/A genotypes at Ϫ1023 showed the significantly lower AUC of SN-38 than those with G/G (pϭ0.018) ( Table 5 ). The AUC of SN-38 seen in patients heterozygous or homozygous for polymorphisms at Ϫ1549, Ϫ1019, Ϫ24 and 3972 was significantly higher than that seen in patients without the respective polymorphisms (pϭ0.026, 0.026, 0.026 and 0.023, respectively), although the haplotype III that consisted of these polymor- phisms was not related to the lower AUC of SN-38 (pϾ0.05).
Association of ABCC2 Diplotypes or Genotypes with Irinotecan-Induced Toxicity
The grade 3 or higher neutropenia observed in patients heterozygous or homozygous for 1249GϾA or haplotype IV was 17% (1/6), while that observed in patients who did not carry the polymorphism or the haplotype was 40% (10/25) ( pϾ0.05). Among our patients receiving FOLFIRI, only one patient suffered from grade 3 diarrhea. Therefore, we could not examine the association of the ABCC2 genotypes or diplotypes with severe diarrhea.
DISCUSSION
This study provides evidence for a genetic predisposition of ABCC2 to interindividual variability in PK profiles of irinotecan and SN-38 in Japanese patients with metastatic colorectal cancer treated with FOLFIRI. The presence of the 1249GϾA that causes the amino acid change (V417I) resulted in the lower AUC of irinotecan. This polymorphism is located in membrane spanning domain 2 in ABCC2 protein.
According to Toh et al., 17) mutations in the membrane spanning domain could change the specificity of its substrates but not its transporter activity. In accordance with the consideration, Choi et al. 18) have demonstrated that the 1249GϾA did not alter the transport activity of ABCC2 by in vitro study. Recently, Kroetz et al. 19) have demonstrated that the 1249GϾA substitution in the ABCC2 gene is associated with gene expression in the human liver, although the mechanism is unclear. They demonstrated that the patients carrying the variant 1249GϾA had significantly higher mRNA level than those with the wild G allele. Consistent with the results, patients with the haplotype IV consisting of 1249GϾA showed the lower AUC of irinotecan, probably because of higher irinotecan clearance caused by a higher mRNA level of ABCC2. de Jong et al. 20) have demonstrated that patients with the haplotype ABCC2*2 which contained the wild G allele at 1249 showed the lower irinotecan clearance comparing to those with haplotypes containing the variant A allele at 1249, that might be partly in accordance with our results. ABCC2*2 also consisted of G at Ϫ1549 (wild), G at Ϫ1019 (variant), C at Ϫ24 (wild), T at IVS26 Ϫ34 (wild) and C at 3972 (wild). The Ϫ1023GϾA was not analyzed by de Jong et al., 20) but we showed that the polymorphism was not related to the lower AUC of irinotecan (Table 5 ). On the other hand, IVS26 Ϫ34TϾC was not examined by us. As described in Table 3 , another difference in the polymorphisms between the haplotype IV and ABCC2*2 was A or G allele at Ϫ1019. However, the role of the Ϫ1019GϾA has not been clarified well. Therefore, we considered that G allele at 1249 seen in both haplotype IV and ABCC2*2 might partly cause the lower AUC of irinotecan, although the contributions of the Ϫ1019GϾA and IVS26 Ϫ34TϾC should be clarified.
We found that the Ϫ1023GϾA polymorphism in the ABCC2 gene and haplotype I containing the polymorphism were related to the lower AUC of SN-38. However, the mechanism of the increase of SN-38 clearance by Ϫ1023GϾA is unclear at present. Further studies are needed to elucidate the function of the polymorphism.
Han et al., 21) found no association between genotypes in ABCC2 (Ϫ24CϾT and 3972CϾT) and the AUC or clearance of irinotecan, SN-38 and SN-38G in 107 advanced non-small cell lung cancer patients treated with irinotecan and cisplatin. 2140 Vol. 31, No. 11 In contrast to these results, the AUC of SN-38 seen in patients heterozygous or homozygous for polymorphisms at Ϫ24 or 3972 was significantly higher than that seen in patients without these polymorphisms (Table 5) , although the haplotype III that consisted of these polymorphisms was not related to the lower AUC of SN-38. The other polymorphisms might contradict the effects of these polymorphisms. It should be noted that patients possessing A/A or G/A genotypes at 1249 resulted in the lower AUC of irinotecan as well as that of SN-38 and SN-38G than others, although the differences seen in the AUC of SN-38 and SN-38G were not significant (Table 5 ). In addition, the effects of other polymorphisms on the AUC of irinotecan, SN-38 and SN-38G showed tendency as follows: some polymorphisms decreased all of the AUC of these compounds, whereas others increased all of the AUC. These results suggest that all of the AUC of these three compounds is related to the ABCC2 activity.
The interpatient variability in PK of irinotecan, SN-38 and SN-38G has been explained by the genetic polymorphisms in the UGT1A1 gene, especially by the UGT1A1*28. 3, 5, 6) In this study, there was one patient heterozygous for the UGT1A1*28 among the 31 patients. The allele frequency of the UGT1A1*28 was 0.016. One of primary reasons for the low frequency of UGT1A1*28 was that 19 patients out of 31 patients also participated in phase II study of FOLFIRI performed in our institute where patients without UGT1A1*28 were enrolled. The low frequency of the UGT1A1*28 allele might emphasize the effects of ABCC2 genotypes on the variability of PK of irinotecan and its metabolites.
On the other hand, one patient was homozygous for and 7 patients were heterozygous for the UGT1A1*6 in the present study. The allele frequency was 0.15. Han et al. 8) have demonstrated the significant relation of UGT1A1*6 genotype with AUC of SN-38 in Korean patients with non-small cell lung cancer, but not with AUC of irinotecan and SN-38G. However, no correlations between the UGT1A1*6 and AUC of SN-38, irinotecan and SN-38G was observed in the present study. In the study of Han et al., 8) the AUC of SN-38 seen in patients homozygous for the UGT1A1*6 was 1.76 times higher than those without the variant, whereas that seen in patients heterozygous for the UGT1A1*6 was only 1.11 times higher than those without the variant. Therefore, the effects of heterozygote of UGT1A1*6 on the AUC of SN-38 is low, although those of homozygote of UGT1A1*6 is high. The low frequency of the homozygote of the UGT1A1*6 might be a cause for no correlations between the UGT1A1*6 and AUC of SN-38 seen in the present study. These might also emphasize the effects of ABCC2 genotypes on the PK of irinotecan and its metabolites.
de Jong et al. 20) have demonstrated that the ABCC2*2 haplotype is associated with the lower incidence of severe diarrhea. However, we could not examine the association of the ABCC2 genotype or diplotypes with severe diarrhea, since only one patient suffered from grade 3 diarrhea. In the present study, the grade 3 or higher neutropenia observed in patients heterozygous or homozygous for 1249GϾA or haplotype IV was 17% (1/6), while that observed in patients who did not carry the polymorphism or the haplotype was 40% (10/25) (pϾ0.05). The lower trend of hematologic toxicity seen in patients with haplotype IV might be in part attributed to the lower systemic exposure to irinotecan, although the present results were insufficient to warrant genotype-based individualization of irinotecan dosing because of the statistical results.
Five patients who were also enrolled in the phase I study of FOLFIRI performed in our institute were treated with 150 mg/m 2 of irinotecan. The tumor response as well as adverse reaction were not significantly different between patients treated with 150 mg/m 2 and 180 mg/m 2 of irinotecan. In conclusion, the present exploratory study revealed that genetic polymorphisms in the ABCC2 play roles in altering systemic exposure of irinotecan and SN-38 in Japanese patients with metastatic colorectal cancer receiving FOLFIRI. Haplotype IV that consisted of 1249GϾA allele and haplotype I containing Ϫ1023GϾA of the ABCC2 gene are associated with lower systemic exposure of SN-38 and irinotecan, respectively.
